The approved product is the generic version of Zebeta (marketed by Teva Pharmaceuticals) and is indicated for the management of hypertension.
JB Chemicals & Pharmaceuticals manufactures a wide range of pharmaceutical formulation specialties, radio-diagnostics, APIs, and intermediates.
The company's consolidated net profit jumped 21.7% to Rs 162.49 crore on a 14.1% rise in net sales to Rs 963.49 crore in Q3 FY25 over Q3 FY24.
Shares of JB Chemicals & Pharmaceuticals rose 0.47% to Rs 1,652.95 on the BSE.